The objectives of this clinical study were to demonstrate a reduction in exposure to selected harmful and potentially harmful constituents (HPHCs), and to assess product use behavior, in Japanese healthy adult smokers who switched to a novel tobacco vapor product (NTV). 60 smokers were randomly assigned for 5 days to either (a) a group who switched to an NTV (n = 20), (b) a group who continued to smoke their own brand of conventional cigarettes (CC, n = 20) or (c) a smoking abstinence group (SA, n = 20). Fifteen biomarkers of exposure (BoEs) to 14 HPHCs and pyrene were measured at baseline, day 3 and 5. Product use behavior was assessed by measuring product consumption, nicotine uptake and puffing topography. During investigations, increases were observed in product consumption and total puff volume in NTV group subjects as compared to baseline. Additionally, nicotine uptake in the NTV group was approximately half that observed in the CC group. BoE values were significantly reduced in the NTV group as compared to those in the CC group. Significantly, the magnitude of the reduction in exposure to HPHCs observed in the NTV group (49-94%) was close to that observed for the SA group (39-95%).
Introduction
Previous studies have reported that cigarette smoking is a risk factor for several diseases such as lung cancer, pulmonary disease and cardiovascular disease (Forey et al., 2011; U.S. Department of Health and Human Services, 2004; Benjamin et al., 2017) . The use of other traditional tobacco products, such as cigars, pipes, and nasal or oral snuff, have also been identified as a risk factor for diseases such as cancer and cardiovascular disease (IARC, 2004 (IARC, , 2007 .
In recent years, there has been an increasing interest in the development of novel tobacco products that could achieve tobacco risk reduction. In the first report, the Institute of Medicine (IOM, 2001 ) reviewed the scientific basis for tobacco harm reduction and came to the conclusion that reducing the risk of disease by reducing exposure to tobacco toxicants is a feasible goal. The IOM went further by defining the key characteristics of a potential reduced-exposure product (PREP). In 2009, the U.S. Family Smoking Prevention and Tobacco Control Act defined a modified risk tobacco product (MRTP) as any tobacco product that is sold or distributed for use to reduce harm or the risk of particular diseases related to marketed tobacco products. The Food and Drug Administration (FDA, 2012a) issued draft guidance for industry on regulatory applications for MRTP, in which the FDA recommended that human studies should be conducted to evaluate the exposure of harmful substances or to evaluate the impact of tobacco products on health. In addition, the FDA (2012b) published a preliminary list of the harmful and potentially harmful constituents (HPHCs) of tobacco products.
Recently, several European countries, such as Italy, Bulgaria, and Cyprus, have incorporated reduced-risk approval provisions into their national transpositions of EU Directive 2014/40/EU. Similar to the USA, these provisions state that human studies should be conducted to evaluate the reduced-risk potential of a particular product.
Some novel tobacco and nicotine containing products, such as electronic vapor products O'Connell et al., 2016) , electronically heated tobacco products (Haziza et al., 2016a; Lüdicke et al., 2017; Gale et al., 2017) and carbon-heated cigarette products (Sakaguchi et al., 2014; Ogden et al., 2015; Lüdicke et al., 2016) , have been designed to reduce exposure to tobacco toxicants. Furthermore, many human clinical studies have been done for such novel products, and these studies have reported reduction in some biomarkers of exposure (BoEs) to selected HPHCs who switched to use the novel product from conventional cigarettes O'Connell et al., 2016; Haziza et al., 2016a; Lüdicke et al., 2016 Lüdicke et al., , 2017 . The novel tobacco vapor product (NTV) evaluated in the present study is a new form of electronically heated tobacco product developed by Japan Tobacco Inc. Takahashi et al. (2017) reported results of the chemical analysis and in vitro toxicity testing of aerosol generated from the NTV and showed that most of the measured selected cigarette smoke constituents were below quantifiable levels. In addition, no measureable genotoxicity or cytotoxicity was found following in vitro testing of the NTV aerosol, in contrast to results obtained using the standard Kentucky reference 3R4F cigarette. Such results would suggest that switching from conventional cigarettes to the NTV examined in the present study reduces exposure to cigarette smoke constituents. Furthermore, switching from conventional cigarettes to the NTV could potentially result in a reduced health risk to the user as compared to the risk associated with conventional tobacco use.
The primary objective of the present study was to determine the exposure to selected HPHCs when subjects were switched from their own brand of conventional cigarettes to an NTV for 5 days. Smoking abstinence was used as a benchmark for exposure to HPHCs. Secondary objectives were to investigate the nicotine uptake, product consumption, and puffing behavior of the examined NTV as compared to conventional cigarettes.
Material and methods

Study design
This study was a controlled, randomized, 3-arm parallel, singlecenter study. The study was conducted at Fukuoka Mirai Hospital in Japan under confined conditions. 60 eligible smokers checked into the clinic in the evening of Day −2 and were randomly assigned into one of the three study groups (a group who switched to an NTV, a group who continued to smoke their own brand of conventional cigarettes [CC] , and a smoking abstinence group [SA]) with similar gender ratio on Day −1 after the inclusion/exclusion criteria had been assessed. During the study period, all tobacco products were dispensed by the site staff one by one and subjects' instructed product consumption was individually managed. On Day −1, subjects smoked their own brands of CC ad libitum within ± 10% of their self-reported daily consumption. From Day1 to Day5, subjects in the CC and NTV groups were allowed to use their assigned tobacco product in separate rooms from 9:00 a.m. to 10:30 p.m. Subjects in the NTV group used the NTV ad libitum but limited to 10 tobacco capsules per day to reflect usual smoking frequency. Subjects in the CC group continued to smoke their own brands of CC ad libitum within ± 10% of their self-reported daily consumption. Subjects in the SA group abstained from smoking and were denied access to all smoking rooms. On Day 6, subjects were discharged during the morning after undergoing safety assessment procedures.
The study was approved by the Institutional Review Board of Japan Tobacco Inc. and the medical institution, conducted in accordance with Good Clinical Practice and the Declaration of Helsinki, and registered at the UMIN Clinical Trials Registry (UMIN000025777). All participants provided written informed consent to participate in the study.
Subjects
Healthy male and female Japanese adult smokers aged 21-65 years were eligible to participate if they smoked an average of 11 or more manufactured cigarettes per day at screening, had smoked for at least 12 months before entering the trial and had a positive result for a urinary cotinine test (One Step Cotinine Test Device, Accuracy-One Inc., California, USA). Before enrollment, the health conditions of participants were confirmed by physical examination, medical history, vital signs, electrocardiogram and clinical laboratory tests. Pregnant or breast-feeding females were excluded from this study. Males having a body mass index (BMI) of less than 18.5 or greater than 27.7 kg/m 2 and females having a BMI of less than 16.8 or greater than 26.1 kg/m 2 were excluded. Participants were also excluded if they had used any prescription drugs, over-the-counter medications (including smoking-cessation medications) or dietary supplements within 2 weeks prior to the investigational period; or if they had used any tobacco products other than commercial cigarettes (i.e., hand-rolled cigarette, cigarillo, cigars, pipes, snuff tobacco, chewing tobacco, etc.) within 1 week before screening. A previous study found that delivered vapor chemistry from the NTV examined in the present study showed similar trends to vapor chemistry results obtained for another non-combustion inhaler type tobacco product (Takahashi et al., 2017; Miura et al., 2015) . Therefore, sample size determination for the present study was based on the levels of biomarkers of exposure observed in subjects who previously used the non-combustion inhaler type of tobacco product used in the Miura et al. (2015) study. A sample size of 20 subjects in each group was considered sufficiently powered for detecting a relative effect between the NTV and CC groups with a two-sided probability of 5% for type I error and an 80% for type II error.
Test tobacco product
The NTV consists of a battery, a cartridge with a heater and liquid, and a tobacco capsule filled with tobacco blend (Supplementary Fig. 1 ). The NTV generates a nicotine-free vapor via electrical heating of a liquid, which contains glycerin, propylene glycol, triacetin and water and does not contain nicotine and flavor unlike many other major e-liquids for electronic cigarettes. The vapor then passes through the tobacco capsule. In doing so, evaporated constituents arising from the tobacco blend, including nicotine and flavors, pass into the vapor, which can then be inhaled by the user. The vapor chemistry of the NTV has been reported previously (Takahashi et al., 2017) .
The sensor unit of the battery accumulates the total puffing duration, and the LED, which is located at the tip of the battery, indicates the replacement timing of the tobacco capsule by blinking when the tobacco capsule requires replacing i.e. when the cumulative puffing duration reaches 120 s. A single tobacco capsule can persist for approximately 50 puffs depending on users puffing duration, and one cartridge can be used for five tobacco capsules. The visibility of the LED blinking has been improved from the prototype NTV used in previous study (Yuki et al., 2017) .
Assessment
Baseline characteristics
The baseline characteristics of subjects, included gender, age, BMI, smoking history, the ISO tar yield of the subject's usual brand of CC, daily cigarette consumption and score on the Fagerström Test for Nicotine Dependence (FTND, Heatherton et al., 1991) were all recorded at screening.
Biomarkers of exposure
BoEs to selected HPHCs published by the Food and Drug Administration (FDA, 2012b) were chosen. 14 HPHCs (acrolein, acry-
, o-toluidine) were selected. These HPHCs were selected because: (a) these constituents (or their metabolites) are easily detectable using validated, reliable, reproducible, and precise analytical methods; (b) the levels of BoEs to these constituents are well described in smokers and non-smokers; and (c) the BoEs to these constituents are widely used for assessing exposure in humans as a result of using tobacco products (Scherer, 2005 BoE to BaP and is an accepted representative constituent of polycyclic aromatic hydrocarbon (PAH). BoE to pyrene was also evaluated in this study. Additionally, the BoE to nicotine was also measured to assess nicotine uptake. In total, 16 BoEs were assessed in this study (Supplementary Table 1) .
The exhaled CO level of subjects was measured by using a piCO
30 min and 45 min after the subject had started to smoke the subjects' usual brand of CC between 5:00 p.m. and 7:00 p.m. on Day −1. For the NTV and CC groups, the exhaled CO level was measured between 30 min and 45 min after the subject had started to use their assigned product between 5:00 p.m. and 7:00 p.m. on Day 3 and Day 5. For the SA group, the exhaled CO level was measured between 5:00 p.m. and 7:00 p.m. on Day 3 and Day 5. The 24hr urine samples for measuring 15 BoEs (3-hydro-
, o-toluidine, and nicotine equivalents [the molar sum of nicotine and the five major metabolites]) were pooled from the morning on Day −1, 3, and 5 to the next morning. The pooled urine volume was also measured for 24hr urines to assess the total mass of daily exposure to selected measured constituents. All urinary BoEs were determined by liquid chromatography-tandem mass spectrometry and bioanalytical methods utilized for measurement of all urinary biomarkers have been reported (Urban et al., 2003; Riedel et al., 2006; Roethig et al., 2007; Ding et al., 2009; Kavvadias et al., 2009; Ramsauer et al., 2011; Haziza et al., 2016b) . All laboratory analyses were carried out using validated methods at Celerion Laboratories (Lincoln, NE, USA and Zurich, Switzerland) according to applicable Good Laboratory Practices.
Product consumption and puffing topography
CC and NTV consumption (number of tobacco capsules) were recorded for all subjects from Day −1 until Day 5, and all products were dispensed by the site staff at the subject's request. Tobacco capsules for NTV were counted one at a time and the blinking of the LED indicated the replacement timing of tobacco capsules. If a tobacco capsule remained unfinished in use on Day 5, it was counted as 0.5 of a capsule used.
For the subjects who were assigned to the NTV and CC groups, the puffing topographies (number of puffs, puff volume, puff duration) were recorded by using the CReSSmicro™ (Plowshare/Borgwaldt KC, Germany) during one CC smoking period between 2:00 p.m. and 7:00 p.m. on Day −1. For the NTV and CC groups, the subjects used the NTV once (maximum 10 min) or smoked one CC using the CReSSmicro™ for the puff topography recording between 2:00 p.m. and 7:00 p.m. on Day 1, Day 3, and Day 5. The medians of puff volume and puff duration were used as the representative values for subjects for each individual assessment. The total puff volume and number of puffs were calculated from the recorded puffing topographies for one NTV use (maximum 10 min) and one CC smoking period. Since an NTV tobacco capsule is designed to be replaced when a cumulative puff duration of 120 s is reached, the total number of puffs per day for the NTV was estimated by using the puff duration during the puffing topography assessment and the daily capsule consumption. The total number of puffs per day for the CC products was estimated by using the number of puffs recorded during the topography assessment and the daily cigarette consumption. The time period of puffing topography assessment for NTV was limited to 10 min, because the CReSSmicro™ is pre-set by the manufacturer to stop recording topography data after a user reaches 40 puffs. The puffing topography was not assessed in subjects who smoked slim CCs that were not compatible with the CReSSmicro™.
Safety
Safety outcomes included an assessment of adverse events (AEs), which included changes in vital signs, clinical laboratory values, and physical examinations.
Statistical analysis
The BoEs to HPHCs and pyrene were analyzed in randomized subjects who had at least one BoE assessment after post-randomization. The differences in the ln-transformed values of the BoE between investigational tobacco products were evaluated using analysis of covariance, with the endpoints observed at the end of exposure (i.e., Day 5 or the last available measurement), group (NTV, CC) as the explanatory variable, and the baseline (Day−1) value as a covariant (two-sided significance level = 0.05). The point estimates of the geometric mean ratios (NTV/CC) and 95% confidence intervals of the ratio were also calculated. The percent changes of the BoEs observed at the end of exposure as compared to baseline were derived for the three study groups.
Descriptive statistics were presented to describe the nicotine equivalents results, daily product consumption, total puff volume, number of puffs, puff volume, puff duration, and total number of puffs per day by study group for each assessment.
All statistical analyses were performed using Statistical Analysis Software (SAS), version 9.3 (SAS Institute Inc., North Carolina, USA).
Results
Study population
Sixty subjects were enrolled in the study, were randomized in accordance with the determined sample size, and completed the study. No major protocol deviations were reported. There was no difference between any of the three groups in terms of gender, age, BMI, the ISO tar yield of the subject's usual brand of CC, daily cigarette consumption and FTND score (Table 1) . Abbreviations; FTND = Fagerström Test for Nicotine Dependence; CC = conventional cigarettes group; NTV = novel tobacco vapor product group; SA = smoking abstinence group.
Product consumption and puffing topography
Subjects in the CC group smoked approximately 16 cigarettes (range: 10-36 cigarettes) per day and it was confirmed that they kept their daily cigarette consumption of CC within ± 10% of their self-reported daily consumption throughout the investigational period. The mean of the daily NTV consumption increased from 3.3 capsules (range: 1.0-7.0 capsules) on Day 1-6.1 capsules (range: 1.5-10.0 capsules) on Day 5 (Supplementary Fig. 2) .
Topography parameters are shown in Table 2 at baseline, Day 1, Day 3, and Day 5 for the NTV and CC groups. The baseline values for each of the assessed puffing topography parameters were similar in the NTV and CC groups, whilst subjects were smoking their own preferred brand of CC and were generally stable in the CC group throughout the investigational period. In the NTV group, the mean of the total puff volume on Day 1 increased approximately by 1.5 times that obtained at baseline and the mean of the total puff volume increased from Day 1 to Day 5.
Biomarkers of exposure
Levels of BoEs to 14 HPHCs and pyrene are presented in Table 3 at baseline, Day 3, and Day 5 for the NTV, CC and SA groups. With the exception of 1-OHP, the BoE were generally stable in the CC group. The BoEs decreased in the NTV and SA groups from baseline to Day 3 and decreased generally or were stable between Day 3 and Day 5. In all groups, 1-OHP decreased from baseline to Day 3 and then increased from Day 3 to Day 5.
Substantial reductions in the levels of all 15 BoEs were observed in the NTV group relative to the CC group on Day 5, with approximately 63% percent reductions (ratio 36.7) in 3-HPMA, 86% (ratio 13.6) in CEMA, 85% (ratio 14.9) in 4-ABP, 94% (ratio 5.9) in 1-NA, 90% (ratio 10.0) in 2-NA, 87% (ratio 13.1) in S-PMA, 67% (ratio 33.2) in 3-OHBaP, 84% (ratio 15.8) in MHBMA, 73% (ratio 26.5) in HBMA, 86% (ratio 13.8) in exhaled CO, 66% (ratio 33.5) in HEMA, 59% (ratio 41.0) in NNAL, 81% (ratio 19.2) in NNN, 67% (ratio 32.8) in o-toluidine, 39% (ratio 60.6) in 1-OHP (Table 4) .
The relative changes from baseline to Day 5 were similar between the NTV and SA groups for each BoE, except for total NNN and 1-OHP (Fig. 1) . For total NNN, the relative change in the NTV group was slightly smaller than SA group.
1-OHP decreased from baseline to Day 3 and then approached to baseline values on Day 5 in the NTV and SA groups but 1-OHP showed a slight decrease from baseline to Day 3 and then increased markedly on Day 5 in the CC group.
Nicotine uptake
The nicotine uptake, measured at baseline, Day 3, and Day 5 by nicotine equivalents was generally stable in the CC group (Table 3) . The nicotine uptake decreased in the NTV and SA groups from baseline to Day 3 and also decreased in the SA group on Day 5 but increased slightly in the NTV group (Table 3) . The relative changes from baseline to Day 5 for nicotine uptake in the NTV group were approximately midway between those observed for the CC and SA groups (Fig. 1) .
Safety
There were no AEs reported during the study.
Discussion
We found that switching to the examined NTV for 5 days led to a significant reduction in 15 BoEs related to the following 14 HPHCs; acrolein, acrylonitrile, 4-ABP, 1-NA, 2-NA, benzene, BaP, 1,3-butadiene, CO, crotonaldehyde, ethylene oxide, NNK, NNN, and o-toluidine and pyrene, as compared to continued smoking. The mean levels of reduction from baseline of these BoEs in the NTV group (except for total NNN and 1-OHP), ranged from 49% to 94%, and the mean magnitude of reduction from baseline was similar between the NTV and SA groups for each BoE measured in the study. Although the study was too short to fully assess the reduction in exposure to NNK with NTV product use because of the 10-to 18-day half-life of NNAL (Goniewicz et al., 2009) , the mean level of reduction from baseline on Day 5 in both the NTV (63%) and SA groups (62%) indicate that NTV product use decreased the exposure to NNK almost as effectively as SA.
For total NNN, the mean level of reduction from baseline was slightly smaller in the NTV group (70%) as compared to the SA group (93%). Takahashi et al. (2017) reported that the NNN level measured for the NTV aerosol (same product as used in the present study) was below quantifiable levels. On the other hand, Stepanov et al. (2009a, b) suggested that NNN may be found in subjects who quit smoking but who use a nicotine patch, nicotine gum or a nicotine lozenge. Knezevich et al. (2013) suggested that NNN can be metabolically formed from nornicotine in some users of oral nicotine replacement products. Although it remains unknown whether endogenous formation of NNN At baseline, all subjects in the NTV and CC groups smoked their usual brand of cigarette. a n = 19 at baseline because the puffing topography could not be assessed for one subject who smoked slim cigarette. b n = 18 through the study period because the puffing topography could not be assessed for two subjects who smoked slim cigarettes.
also occur in users of inhaler type of nicotine containing products, the difference observed in the present study in the magnitude of total NNN reduction between the NTV and SA groups, might be explained by endogenous formation of NNN. With respect to pyrene, the 1-OHP level obtained in the present study was significantly lower in subjects using the NTV for 5 days as compared to subjects who continued to smoke their own CC. The substantial reduction in 1-OHP observed for subjects in the NTV use group was approximately 39%, as compared to the 1-OHP result obtained for subjects in the CC group, although the mean level of change from baseline was −5% in the NTV group. The mean levels of change in 1-OHP from baseline were +12% in the SA group and +55% in the CC group and 1-OHP levels increased from Day 3 to Day 5 in all groups.
Cooking food using certain methods (e.g., smoking, grilling, or barbecuing) can generate PAH. Such generation of PAH during cooking procedures is recognized as the major source of PAH exposure for nonoccupationally exposed nonsmokers (EFSA, 2008) . In the present study, subjects received standardized meals and it was confirmed that subjects received many foods that potentially could have resulted in increased PAH exposure such as; fried chicken and baked fish in the latter part of the study period. Furthermore, the mean level of increase from Day 3 to Day 5 was similar (144-168 ng/24hr) between all groups. With respect to other BoE to PAH measured in the present study, 3-OH-BaP level increased slightly in all groups from Day 3 to Day 5 (22-38 pg/24hr) but the general level of increase observed was smaller than was observed for 1-OHP. It is considered that PAH levels in the present study subjects were affected by a lack of dietary restriction and as such that the evaluation of pyrene from tobacco product in this study is confounded. Therefore, dietary restrictions should be considered in future studies.
The mean daily NTV consumption on Day 5 was nearly double that recorded on Day 1 and five subjects used 10 capsules, which was subsequently set as the daily maximum limit of capsule consumption on Day 4 and 5. Subjects in the NTV group took approximately 249 puffs 14.0 ± 7.9 132.0 ± 74.4 13.6 ± 5.6 Day 5
12.4 ± 6.6 118.1 ± 64.7 11.7 ± 4.6 4-ABP (ng/24hr) Baseline 13.4 ± 5.6 14.6 ± 6.6 13.0 ± 5.6 Day 3 2.8 ± 0.9 14.0 ± 6.2 2.7 ± 0.8 Day 5
1.8 ± 1.0 12.3 ± 5.7 1.6 ± 0.6 1-NA (ng/24hr) Baseline 94.1 ± 40.9 101.6 ± 51.2 100.7 ± 52.9 Day 3
11.8 ± 6.5 104.3 ± 50.7 12.2 ± 7.6 Day 5
5.7 ± 3.2 93.6 ± 45.8 4.5 ± 2.3 2-NA (ng/24hr) Baseline 26.9 ± 11.6 27.9 ± 13.4 27.4 ± 12.8 Day 3
2.4 ± 1.0 27.4 ± 13.4 2.7 ± 1. per day for the CC at baseline and the mean daily total number of puffs increased from 220 puffs on Day 1-344 puffs on Day 5. Although the mean daily NTV consumption on Day 5 was nearly double that recorded on Day 1, the mean daily total number of puffs on Day 5 was approximately 1.5 times that obtained on Day 1 due to an increase in the puff durations from Day 1 to Day 5. With respect puffing topography of the NTV, the total puff volume was doubled for CC on Day 5. In our previous study, higher total puff volumes and longer puff durations resulted in higher amounts of nicotine delivered from the prototype NTV (Yuki et al., 2017) . Furthermore, the nicotine uptake decreased in the NTV group from baseline to Day 3 and then increased slightly on Day 5 but the mean relative change from baseline was −47% in the NTV group.
We performed a subgroup analysis based on the tobacco capsule consumption of Day 5 (high-consumption: > 7.0 capsules [n = 8], middle-consumption: 5.0-7.0 capsules [n = 4], low-consumption: < 5.0 capsule [n = 8]). The mean daily NTV consumption increased from 4.4, 4.0 and 1.8 capsules on Day 1-9.3, 5.9 and 3.0 capsules on Day 5 in the high-consumption, middle-consumption and low-consumption subgroups. With respect puffing topography on Day 5, all assessed topography parameters of the high-consumption subgroup were higher or longer than those of the middle-consumption and low-consumption subgroups. Although there was no difference in the mean levels of reduction from baseline of 15 BoEs between three subgroups, the mean relative changes of the nicotine uptake from baseline were slightly difference, and were −22% in the high-consumption subgroup, −52% in the middle-consumption subgroup, and −66% in the low-consumption subgroup. There was no remarkable difference between any of the three subgroups in terms of demographic characters, but the mean levels of nicotine uptake on baseline were slightly difference between three subgroups, and were 11.5 mg/24hr in the high-consumption subgroup, 9.1 mg/24hr in the middle-consumption subgroup, and 7.3 mg/24hr in the low-consumption subgroup. It was reported that smokers had changed their product use behavior after switching to the new tobacco product, adjusting the nicotine uptake level themselves (Scherer, 1999; Trtchounian et al., 2010; Farsalinos et al., 2015 Farsalinos et al., , 2017 Lüdicke et al., 2016) . Results obtained in the present study suggest that subjects in the NTV group changed their product use behavior adapting to the NTV during the study period, and the nicotine uptake level at baseline might be one of factors of change in product use behavior. However, the fixed daily limit of capsule consumption meant that this change in product use behavior was restricted for some subjects.
In conclusion, results obtained in the present study confirm that switching to the NTV for 5 days resulted in substantial reductions in subject exposure to selected HPHCs. The NTV group of subjects yielded reductions in HPHC exposure levels similar to the SA group, despite the increases in daily capsule consumption and puffing behavior after switching to the NTV. Retrospectively, the limitation of the present study was that the daily capsule consumption was limited and the study duration was only 5 days. In future, any evaluation of the reduction of exposure to HPHCs will require long-term clinical studies that allow subjects to adapt their behavior to NTV product use without limiting Fig. 1 . Relative change (%) from baseline to end of exposure by study group. Abbreviations; 1-OHP = 1-hydroxypyrene; 1-NA = 1-naphthylamine; 2-NA = 2-naphthylamine; 3-HPMA = 3-hydroxypropyl-mercapturic acid; 3-OHBaP = 3-hydroxy-benzo[a]pyrene; 4-ABP = 4-aminobiphenyl; CO = carbon monoxide; CEMA = 2-cyanoethylmercapturic acid; HEMA = 2-hydroxyethylmercapturic acid; HBMA = 4-hydroxybutyl-2-mercapturic acid; NNAL = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; MHBMA = monohydroxybutenylmercapturic acid; NNN = N-nitrosonornicotine; S-PMA = S-phenylmercapturic acid; CC = conventional cigarettes group; NTV = novel tobacco vapor product group; SA = smoking abstinent group. the daily consumption of NTV. Additionally, it would be beneficial to evaluate whether reduced HPHC exposure is associated with reduced risk of smoking related diseases by evaluation of candidate biomarkers of potential harm.
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